Thomas Nitschke Kledal

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 5

Top Topics

Respiratory Syndrome Coronavirus

Molecular Docking

Top Venues

Communications biology

This page only lists publications with an associated author ORCID identifier.

Publications

Trine L Toft-Bertelsen, Mads Gravers Jeppesen, Asante Landbrug, Amer Mujezinovic, Bo Hjorth Bentzen, Thomas Nitschke Kledal, Mette Marie Rosenkilde
Reply to: How Many SARS-CoV-2 "Viroporins" Are Really Ion Channels? Communications biology 5 (1) (2022)
Trine L Toft-Bertelsen, Mads Gravers Jeppesen, Asante Landbrug, Amer Mujezinovic, Bo Hjorth Bentzen, Thomas Nitschke Kledal, Mette Marie Rosenkilde
Publisher Correction: Reply to: How many SARS-CoV-2 "viroporins" are really ion channels? Communications biology 5 (1) (2022)
Julius Maximilian Knerr, Thomas Nitschke Kledal, Mette Marie Rosenkilde
Molecular Properties and Therapeutic Targeting of the EBV-Encoded Receptor BILF1. Cancers 13 (16) (2021)
Trine Lisberg Toft-Bertelsen, Mads Gravers Jeppesen, Eva Tzortzini, Kai Xue, Karin Giller, Stefan Becker, Amer Mujezinovic, Bo Hjorth Bentzen, Loren B Andreas, Antonios Kolocouris, Thomas Nitschke Kledal, Mette Marie Rosenkilde
Amantadine has potential for the treatment of COVID-19 because it inhibits known and novel ion channels encoded by SARS-CoV-2. Communications biology 4 (1) (2021)
Trine Lisberg Toft-Bertelsen, Mads Gravers Jeppesen, Eva Tzortzini, Kai Xue, Karin Giller, Stefan Becker, Amer Mujezinovic, Bo Hjorth Bentzen, Loren B Andreas, Antonios Kolocouris, Thomas Nitschke Kledal, Mette Marie Rosenkilde
Author Correction: Amantadine inhibits known and novel ion channels encoded by SARS-CoV-2 in vitro. Communications biology 4 (1) (2021)